<a href="https://laohu8.com/S/PAVM">PAVmed Inc.</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)
PAVmed Inc., a diversified commercial-stage medical technology company, reported financial results for the second quarter of 2025. Lucid Diagnostics Inc., a subsidiary of PAVmed, processed 2,756 EsoGuard tests during the quarter, generating $1.2 million in revenue. This marks a significant milestone for the company as it pushes forward with its strategic goals. Additionally, Lucid has secured a meeting on September 4 to discuss Medicare Local Coverage Determination for EsoGuard. Veris Health Inc., another PAVmed subsidiary, completed its second-quarter financing, which allowed it to relaunch the development of its implantable physiological monitor. Veris is taking integration steps to commence the commercial phase in partnership with OSU-The James. These developments reflect PAVmed's strategy to stabilize its corporate structure and strengthen its balance sheet, positioning it as a diversified commercial life sciences entity with multiple independently-financed subsidiaries operating under a shared services model.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023729), on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.